Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Aging
- Epigenetics
- Inflammatory Mediators
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants will be their own control, either right or left arm will be randomized to treatment or placebo.Masking: Double (Participant, Investigator)Masking Description: Randomization will be performed by the compounding pharmacy. Ointment dispensers will be color-coded for left and right arm for each subject.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 65 years and 95 years
- Gender
- Both males and females
Description
Rapamycin 8% ointment will be applied topically to one of the participant's forearms and matching placebo to the opposite forearm daily for a total of 6 months. After consenting, screening and randomization of arms, the participants will be monitored at monthly visits until study completion.
Rapamycin 8% ointment will be applied topically to one of the participant's forearms and matching placebo to the opposite forearm daily for a total of 6 months. After consenting, screening and randomization of arms, the participants will be monitored at monthly visits until study completion.
Tracking Information
- NCT #
- NCT04608448
- Collaborators
- National Institute on Aging (NIA)
- Investigators
- Principal Investigator: Ellen Kraig, PhD University of Texas Health at San Antonio Principal Investigator: Dean L Kellogg, Jr., MD, PhD University of Texas Health at San Antonio
Get Well Soon